Spanish National Cancer Research Centre, Madrid, Spain.
Cancer Lett. 2011 Jan 28;300(2):145-53. doi: 10.1016/j.canlet.2010.09.016. Epub 2010 Nov 3.
The serine/threonine Pim 1 kinase is an oncogene whose expression is deregulated in several human cancers. Overexpression of Pim 1 facilitates cell cycle progression and suppresses apoptosis. Hence pharmacologic inhibitors of Pim 1 are of therapeutic interest for cancer. ETP-45299 is a potent and selective inhibitor of Pim 1 that inhibits the phosphorylation of Bad and 4EBP1 in cells and suppresses the proliferation of several non-solid and solid human tumor cell lines. The combination of the PI3K inhibitor GDC-0941 with ETP-45299 was strongly synergistic in MV-4-11 AML cells, indicating that the combination of selective Pim kinase inhibitors and PI3K inhibitor could have clinical benefit.
丝氨酸/苏氨酸 Pim 1 激酶是一种癌基因,其表达在几种人类癌症中失调。Pim 1 的过表达促进细胞周期进程并抑制细胞凋亡。因此,Pim 1 的药理抑制剂对癌症具有治疗意义。ETP-45299 是一种有效的、选择性的 Pim 1 抑制剂,可抑制细胞中 Bad 和 4EBP1 的磷酸化,并抑制几种非实体瘤和实体瘤人类肿瘤细胞系的增殖。PI3K 抑制剂 GDC-0941 与 ETP-45299 的联合使用在 MV-4-11 AML 细胞中具有强烈的协同作用,表明选择性 Pim 激酶抑制剂与 PI3K 抑制剂的联合使用可能具有临床获益。